INT278820

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.03
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.10
Pain Relevance 0.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transducer activity (EDNRA, EDNRB) plasma membrane (EDNRA, EDNRB) aging (EDNRA)
cell-cell signaling (EDN1) cytoplasm (EDN1) cell proliferation (EDNRA)
Anatomy Link Frequency
superior 4
EDNRA (Homo sapiens)
EDN1 (Homo sapiens)
EDNRB (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 30 97.48 Very High Very High Very High
Inflammation 2 74.32 Quite High
fibrosis 4 73.64 Quite High
Bioavailability 2 60.32 Quite High
Calcium channel 6 50.44 Quite High
headache 6 5.00 Very Low Very Low Very Low
methotrexate 4 5.00 Very Low Very Low Very Low
Angina 4 5.00 Very Low Very Low Very Low
tolerance 4 5.00 Very Low Very Low Very Low
nud 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 196 98.68 Very High Very High Very High
Increased Venous Pressure Under Development 12 93.96 High High
INFLAMMATION 2 74.32 Quite High
Fibrosis 2 73.64 Quite High
Anaemia 10 24.00 Low Low
Pulmonary Fibrosis 2 23.56 Low Low
Disorders Of Creatine Metabolism 2 22.80 Low Low
Dyspnea 18 17.08 Low Low
Disease 30 5.00 Very Low Very Low Very Low
Cv General 4 Under Development 20 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Selective agents with relative ETA:ETB affinity of greater than 100:1 have been developed, eg, sitaxentan, relative affinity 6500:1, which have also been shown to reduce endothelin-1 levels.19 Bosentan exhibits a relative ETA:ETB affinity of 20:1 by in vitro assays and is therefore classed as a dual ERA.20 Although ETA selectivity is attractive, these selective agents have not been shown to be superior to bosentan in clinical trials.
ETA Negative_regulation (reduce) of endothelin-1 Binding (affinity) of ETB in superior associated with antagonist
1) Confidence 0.03 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.55 Pain Relevance 0.18
Selective agents with relative ETA:ETB affinity of greater than 100:1 have been developed, eg, sitaxentan, relative affinity 6500:1, which have also been shown to reduce endothelin-1 levels.19 Bosentan exhibits a relative ETA:ETB affinity of 20:1 by in vitro assays and is therefore classed as a dual ERA.20 Although ETA selectivity is attractive, these selective agents have not been shown to be superior to bosentan in clinical trials.
ETA Negative_regulation (reduce) of endothelin-1 Binding (affinity) of ETB in superior associated with antagonist
2) Confidence 0.03 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.55 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox